Prostate-specific antigen response after Abiraterone treatment in mCRPC: PSA as a predictor of overall survival. Arch Ital Urol Androl [Internet]. 2023 Feb. 22 [cited 2026 May 12];95(1). Available from: https://www.pagepressjournals.org/aiua/article/view/11052